{"title":"Ten-Year Trends in How Early-Stage Sepsis Start-Ups Receive Investment.","authors":"John G Younger, Jacob Jordan, Shintaro Kaido","doi":"10.1097/SHK.0000000000002573","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Often initiated with small governmental or philanthropic grants, nearly all improvements in the detection and care of sepsis require many years and many millions of dollars of financing before becoming generally clinically available. As early-stage healthcare investors are free to pursue a wide variety of new enterprises, innovations in sepsis care must compete in the early investment marketplace by offering both a path to clinical benefit and a path to commercial viability upon commercialization. In this note, we consider the investment environment for sepsis-related technologies including pharmaceuticals and biologicals, diagnostic and therapeutic devices, and health care information technologies and place a decade of investment trends into a broader economic context. Our hope is to better familiarize basic, translational, and clinical scientists with greater insight into how their inventions will be supported as they make their way to the bedside.</p>","PeriodicalId":21667,"journal":{"name":"SHOCK","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SHOCK","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/SHK.0000000000002573","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract: Often initiated with small governmental or philanthropic grants, nearly all improvements in the detection and care of sepsis require many years and many millions of dollars of financing before becoming generally clinically available. As early-stage healthcare investors are free to pursue a wide variety of new enterprises, innovations in sepsis care must compete in the early investment marketplace by offering both a path to clinical benefit and a path to commercial viability upon commercialization. In this note, we consider the investment environment for sepsis-related technologies including pharmaceuticals and biologicals, diagnostic and therapeutic devices, and health care information technologies and place a decade of investment trends into a broader economic context. Our hope is to better familiarize basic, translational, and clinical scientists with greater insight into how their inventions will be supported as they make their way to the bedside.
期刊介绍：
SHOCK®: Injury, Inflammation, and Sepsis: Laboratory and Clinical Approaches includes studies of novel therapeutic approaches, such as immunomodulation, gene therapy, nutrition, and others. The mission of the Journal is to foster and promote multidisciplinary studies, both experimental and clinical in nature, that critically examine the etiology, mechanisms and novel therapeutics of shock-related pathophysiological conditions. Its purpose is to excel as a vehicle for timely publication in the areas of basic and clinical studies of shock, trauma, sepsis, inflammation, ischemia, and related pathobiological states, with particular emphasis on the biologic mechanisms that determine the response to such injury. Making such information available will ultimately facilitate improved care of the traumatized or septic individual.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
